Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
9.12
-0.13 (-1.41%)
At close: Jul 11, 2025, 4:00 PM
9.19
+0.07 (0.77%)
After-hours: Jul 11, 2025, 7:58 PM EDT
Viatris Revenue
Viatris had revenue of $3.25B in the quarter ending March 31, 2025, a decrease of -11.17%. This brings the company's revenue in the last twelve months to $14.33B, down -6.71% year-over-year. In the year 2024, Viatris had annual revenue of $14.74B, down -4.46%.
Revenue (ttm)
$14.33B
Revenue Growth
-6.71%
P/S Ratio
0.76
Revenue / Employee
$447,819
Employees
32,000
Market Cap
10.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
VTRS News
- 2 days ago - Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys - Seeking Alpha
- 17 days ago - Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia - PRNewsWire
- 4 weeks ago - Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 - PRNewsWire
- 4 weeks ago - Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewsWire
- 5 weeks ago - Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - PRNewsWire
- 6 weeks ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - PRNewsWire